Cargando…

Case report: BRAF-inhibitor therapy in BRAF-mutated primary CNS tumours including one case of BRAF-mutated Rosai-Dorfman disease

BRAF V600E oncogene mutations have been reported in multiple central nervous system (CNS) tumor types, and emerging evidence supports the use of targeted therapy in BRAF-mutated gliomas. BRAF oncogene mutations have been recently identified in Rosai-Dorfman disease (RDD)—a rare non-Langerhans cell h...

Descripción completa

Detalles Bibliográficos
Autores principales: Cronin, Christopher, McLaughlin, Ronan, Lane, Louise, Brett, Francesca M., Jansen, Michael, Bermingham, Niamh, Wyse, Gerald, Grogan, Liam, Morris, Patrick G., O’Reilly, Seamus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813211/
https://www.ncbi.nlm.nih.gov/pubmed/36619621
http://dx.doi.org/10.3389/fmed.2022.1070828
_version_ 1784863883720130560
author Cronin, Christopher
McLaughlin, Ronan
Lane, Louise
Brett, Francesca M.
Jansen, Michael
Bermingham, Niamh
Wyse, Gerald
Grogan, Liam
Morris, Patrick G.
O’Reilly, Seamus
author_facet Cronin, Christopher
McLaughlin, Ronan
Lane, Louise
Brett, Francesca M.
Jansen, Michael
Bermingham, Niamh
Wyse, Gerald
Grogan, Liam
Morris, Patrick G.
O’Reilly, Seamus
author_sort Cronin, Christopher
collection PubMed
description BRAF V600E oncogene mutations have been reported in multiple central nervous system (CNS) tumor types, and emerging evidence supports the use of targeted therapy in BRAF-mutated gliomas. BRAF oncogene mutations have been recently identified in Rosai-Dorfman disease (RDD)—a rare non-Langerhans cell histiocytosis. This series describes three patients from two neurosurgical centers in Ireland with BRAF V600E-mutated CNS tumors. The study participants include a 19-year-old male patient with ganglioglioma with anaplastic features, a 21-year-old male patient with CNS involvement of RDD, and a 28-year-old female patient with ganglioglioma with anaplastic features. Two patients received radiation with concurrent temozolomide before BRAF-targeted therapy. This case series describes clinical and radiological responses to BRAF-targeted therapy in BRAF V600E-mutated gliomas across multiple tumor grades and is only the second published report of response to targeted therapy in BRAF-mutated RDD. The durability of disease control with BRAF-targeted therapy was generally superior to that achieved with chemoradiation; one patient has experienced ongoing disease control for 5 years. The reported case of treatment response in BRAF-mutated RDD supports the strategy of genotyping and utilization of targeted therapy in this rare disease. The optimal sequencing of BRAF-targeted therapy in BRAF-mutated gliomas/glioneuronal tumors remains unclear, and further prospective studies are required to guide the use of genome-matched therapy in this patient population.
format Online
Article
Text
id pubmed-9813211
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98132112023-01-06 Case report: BRAF-inhibitor therapy in BRAF-mutated primary CNS tumours including one case of BRAF-mutated Rosai-Dorfman disease Cronin, Christopher McLaughlin, Ronan Lane, Louise Brett, Francesca M. Jansen, Michael Bermingham, Niamh Wyse, Gerald Grogan, Liam Morris, Patrick G. O’Reilly, Seamus Front Med (Lausanne) Medicine BRAF V600E oncogene mutations have been reported in multiple central nervous system (CNS) tumor types, and emerging evidence supports the use of targeted therapy in BRAF-mutated gliomas. BRAF oncogene mutations have been recently identified in Rosai-Dorfman disease (RDD)—a rare non-Langerhans cell histiocytosis. This series describes three patients from two neurosurgical centers in Ireland with BRAF V600E-mutated CNS tumors. The study participants include a 19-year-old male patient with ganglioglioma with anaplastic features, a 21-year-old male patient with CNS involvement of RDD, and a 28-year-old female patient with ganglioglioma with anaplastic features. Two patients received radiation with concurrent temozolomide before BRAF-targeted therapy. This case series describes clinical and radiological responses to BRAF-targeted therapy in BRAF V600E-mutated gliomas across multiple tumor grades and is only the second published report of response to targeted therapy in BRAF-mutated RDD. The durability of disease control with BRAF-targeted therapy was generally superior to that achieved with chemoradiation; one patient has experienced ongoing disease control for 5 years. The reported case of treatment response in BRAF-mutated RDD supports the strategy of genotyping and utilization of targeted therapy in this rare disease. The optimal sequencing of BRAF-targeted therapy in BRAF-mutated gliomas/glioneuronal tumors remains unclear, and further prospective studies are required to guide the use of genome-matched therapy in this patient population. Frontiers Media S.A. 2022-12-22 /pmc/articles/PMC9813211/ /pubmed/36619621 http://dx.doi.org/10.3389/fmed.2022.1070828 Text en Copyright © 2022 Cronin, McLaughlin, Lane, Brett, Jansen, Bermingham, Wyse, Grogan, Morris and O’Reilly. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Cronin, Christopher
McLaughlin, Ronan
Lane, Louise
Brett, Francesca M.
Jansen, Michael
Bermingham, Niamh
Wyse, Gerald
Grogan, Liam
Morris, Patrick G.
O’Reilly, Seamus
Case report: BRAF-inhibitor therapy in BRAF-mutated primary CNS tumours including one case of BRAF-mutated Rosai-Dorfman disease
title Case report: BRAF-inhibitor therapy in BRAF-mutated primary CNS tumours including one case of BRAF-mutated Rosai-Dorfman disease
title_full Case report: BRAF-inhibitor therapy in BRAF-mutated primary CNS tumours including one case of BRAF-mutated Rosai-Dorfman disease
title_fullStr Case report: BRAF-inhibitor therapy in BRAF-mutated primary CNS tumours including one case of BRAF-mutated Rosai-Dorfman disease
title_full_unstemmed Case report: BRAF-inhibitor therapy in BRAF-mutated primary CNS tumours including one case of BRAF-mutated Rosai-Dorfman disease
title_short Case report: BRAF-inhibitor therapy in BRAF-mutated primary CNS tumours including one case of BRAF-mutated Rosai-Dorfman disease
title_sort case report: braf-inhibitor therapy in braf-mutated primary cns tumours including one case of braf-mutated rosai-dorfman disease
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813211/
https://www.ncbi.nlm.nih.gov/pubmed/36619621
http://dx.doi.org/10.3389/fmed.2022.1070828
work_keys_str_mv AT croninchristopher casereportbrafinhibitortherapyinbrafmutatedprimarycnstumoursincludingonecaseofbrafmutatedrosaidorfmandisease
AT mclaughlinronan casereportbrafinhibitortherapyinbrafmutatedprimarycnstumoursincludingonecaseofbrafmutatedrosaidorfmandisease
AT lanelouise casereportbrafinhibitortherapyinbrafmutatedprimarycnstumoursincludingonecaseofbrafmutatedrosaidorfmandisease
AT brettfrancescam casereportbrafinhibitortherapyinbrafmutatedprimarycnstumoursincludingonecaseofbrafmutatedrosaidorfmandisease
AT jansenmichael casereportbrafinhibitortherapyinbrafmutatedprimarycnstumoursincludingonecaseofbrafmutatedrosaidorfmandisease
AT berminghamniamh casereportbrafinhibitortherapyinbrafmutatedprimarycnstumoursincludingonecaseofbrafmutatedrosaidorfmandisease
AT wysegerald casereportbrafinhibitortherapyinbrafmutatedprimarycnstumoursincludingonecaseofbrafmutatedrosaidorfmandisease
AT groganliam casereportbrafinhibitortherapyinbrafmutatedprimarycnstumoursincludingonecaseofbrafmutatedrosaidorfmandisease
AT morrispatrickg casereportbrafinhibitortherapyinbrafmutatedprimarycnstumoursincludingonecaseofbrafmutatedrosaidorfmandisease
AT oreillyseamus casereportbrafinhibitortherapyinbrafmutatedprimarycnstumoursincludingonecaseofbrafmutatedrosaidorfmandisease